Agenus (NASDAQ: AGEN) — Company Overview, News & Financial Data
Agenus is a biotechnology firm developing immunotherapy products for cancer and infectious disease treatments.
Agenus
Agenus (NASDAQ:AGEN) is a biotechnology firm focused on discovering, developing, and commercializing a range of immunotherapy products for treating cancer and infectious diseases. The company's portfolio includes checkpoint antibodies, cell therapies, adjuvants, and vaccines aimed at stimulating the immune response to target and eliminate cancer cells or pathogens. Agenus is dedicated to advancing cure rates and survival for patients while reducing side effects, with a keen emphasis on leveraging its technology platforms to create innovative treatments. Their objective is to harness the power of the immune system to provide new therapeutic options for patients with serious diseases, continuously pushing the boundaries in the field of immunotherapy.
Snapshot
Operations
Products and/or services of Agenus
- QS-21 Stimulon adjuvant, enhances efficacy of vaccines against infectious diseases and cancer.
- Balstilimab, investigational checkpoint inhibitor targeting PD-1 for various cancers.
- Zalifrelimab, investigational CTLA-4 checkpoint inhibitor aimed at cancer treatment.
- AGEN2373, CD137 agonist antibody designed to enhance anti-tumor activity without liver toxicity.
- AGEN1423, a therapeutic antibody that targets immune suppressive mechanisms in the tumor microenvironment.
- AGEN1884, CTLA-4 checkpoint inhibitor targeting T cells for cancer therapy.
Agenus executive team
- Garo H. ArmenFounder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman
- Steven J. O'DayChief Medical Officer
- Jennifer S. BuellDirector and President & CEO of MiNK Therapeutics
- Craig WinterChief Information Officer
- Zack ArmenVice President of Investor Relations & Corporate Development
- Stefanie Perna-NacarChief Communications & Government Relations Officer
- Tracy Mazza ClementeChief People Officer
- Todd Jude YanceyMember of Advisory Board & Chief Strategic Advisor
- Robin G. TaylorChief Commercial Officer
- Kamel DjazouliHead of Medical Affairs
Key financials
Reported results for Agenus, in USD.
- Market cap
- 301.2M
- Revenue (TTM)
- 132.7M
- P/E ratio
- 2.6
- EPS (diluted, TTM)
- 2.6
- Dividend yield
- —
- Profit margin
- 69.3%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 114.2M | -20.6M | 115K | |
| 103.5M | -120.5M | -227.2M | |
| 156.3M | -159.5M | -245.8M | |
| 98M | -179.4M | -220.1M |